Protective Role of Vitamin D in Breast Cancer Patients Treated With Doxorubicin — VDDOXO  

Breast Cancer Clinical Trial

Official title: The Potential Protective Effects of Vitamin (D) Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

Status Completed

Clinical Trial Summary

The study is aimed at Evaluation of the potential protective effect of Vitamin D in doxorubucin- induced toxicity in breast cancer patients.

Proposal Steps:

1. 100 Patients recruited from Alexandria Main University Hospital (AMUH), Oncology Unit are randomly assigned in to two groups:

• Control group (n=50) the patient will receive AC regimen (Doxorubucin & cyclophosphamide) for 4 cycles every 21 day (i.e. 3 months.)

• Vitamin D group (n=50) who will receive 4 Cycles AC regimen in addition to vitamin D (Bon One 0.5 microgram®) once daily.

2. Echocardiography (Echo) will be done at base line and at the end of the treatment.

3. Vitamin D, LDH, Troponin-t as well as IL-6 will be assessed at baseline and at the end of the study.

Clinical Trial Description

Research Objectives: Evaluation of the potential protective effect of Vitamin D in doxorubucin- induced toxicity in breast cancer patients.

Proposal Steps:

1. Assessing breast cancer patients taking part in the study receiving adjuvant chemotherapy AC (Anthracycline (Doxorubucin)-cyclophosphamide) for breast cancer for 4 cycles every 21 day (i.e. 3 months.)

2. 100 Patients are randomly assigned in to two groups:

• Control group (n=50) the patient will receive AC regimen (Doxorubucin & Cyclophosphamide) for 4 cycles every 21 day (i.e. 3 months.)

• Vitamin D group (n=50) who will receive 4 Cycles AC regimen in addition to vitamin D once daily.

3. All participants are recruited from AMUH Hospital Oncology Unit. All participants will be given their consent. The study will be approved by research ethics committee of Damanhour University.

4. Tumor staging is done according to American joint committee on cancer (TNM staging of breast cancer eighth edition (Amin et al., 2017).

5. All patients will be submitted to:

• Full patient history and clinical examination.

• Routine follow up before and after each chemotherapy cycle (complete blood picture, liver function tests, renal function tests.

6. Echocardiography (Echo) at base line and at the end of the treatment.

7. Vitamin D, LDH, Troponin-t as well as IL-6 will be assessed at baseline and at the end of the study.

Methodology:

Venous blood samples will be analyzed using ELISA Vitamin D, IL-6 kits and immuno-histo-chemistry Troponoin-T and LDH and kits. ;

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

• NCT number: NCT04166253
• Study type: Interventional
• Source: Damanhour University
• Status: Completed
• Phase: Phase 2
• Start date: September 1, 2019
• Completion date: May 1, 2020